Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR3 R248C PIK3CA A1066V |
| Therapy | Nintedanib + Pictilisib |
| Indication/Tumor Type | urinary bladder cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR3 R248C PIK3CA A1066V | urinary bladder cancer | sensitive | Nintedanib + Pictilisib | Preclinical - Cell culture | Actionable | In a preclinical study, combination treatment with Ofev (nintedanib) and Pictilisib (GDC-0941) inhibited cell proliferation in a bladder cancer cell line harboring FGFR3 R248C and PIK3CA A1066V in culture (PMID: 36805958). | 36805958 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (36805958) | Tumor and Stromal Cell Targeting with Nintedanib and Alpelisib Overcomes Intrinsic Bladder Cancer Resistance. | Full reference... |